Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease.
Addy C, Assaid C, Hreniuk D, Stroh M, Xu Y, Herring WJ, Ellenbogen A, Jinnah HA, Kirby L, Leibowitz MT, Stewart RM, Tarsy D, Tetrud J, Stoch SA, Gottesdiener K, Wagner J. Addy C, et al. Among authors: assaid c. J Clin Pharmacol. 2009 Jul;49(7):856-64. doi: 10.1177/0091270009336735. Epub 2009 Jun 2. J Clin Pharmacol. 2009. PMID: 19491335 Clinical Trial.
A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease.
Herring WJ, Assaid C, Budd K, Vargo R, Mazenko RS, Lines C, Ellenbogen A, Verhagen Metman L. Herring WJ, et al. Among authors: assaid c. Clin Neuropharmacol. 2017 Nov/Dec;40(6):255-260. doi: 10.1097/WNF.0000000000000241. Clin Neuropharmacol. 2017. PMID: 29059133 Clinical Trial.
Incidence of hypersensitivity and anaphylaxis with sugammadex.
Min KC, Woo T, Assaid C, McCrea J, Gurner DM, Sisk CM, Adkinson F, Herring WJ. Min KC, et al. Among authors: assaid c. J Clin Anesth. 2018 Jun;47:67-73. doi: 10.1016/j.jclinane.2018.03.018. Epub 2018 Apr 3. J Clin Anesth. 2018. PMID: 29621739
A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.
Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, Assaid C, Nessly ML, Norman BA, Baranak CC, Reines SA; Rofecoxib Protocol 078 study group. Thal LJ, et al. Among authors: assaid c. Neuropsychopharmacology. 2005 Jun;30(6):1204-15. doi: 10.1038/sj.npp.1300690. Neuropsychopharmacology. 2005. PMID: 15742005 Clinical Trial.
Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer's disease.
Voss T, Li J, Cummings J, Farlow M, Assaid C, Froman S, Leibensperger H, Snow-Adami L, McMahon KB, Egan M, Michelson D. Voss T, et al. Among authors: assaid c. Alzheimers Dement (N Y). 2018 Apr 26;4:173-181. doi: 10.1016/j.trci.2018.03.004. eCollection 2018. Alzheimers Dement (N Y). 2018. PMID: 29955661 Free PMC article.
27 results